Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Gastrointestinal Cancer: early-phase trial registry
31 of 50 indexed Gastrointestinal Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #277 of 28,707 conditions by registered trial count.
50 US clinical trials · 31 currently recruiting · #277 of 28,707 conditions by registered trial count
Gastrointestinal Cancer: 50 US clinical trials tracked, 31 recruiting.
Gastrointestinal Cancer is the subject of 50 registered US clinical trials on ClinicalTrials.gov, 31 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most active sponsor is Dana-Farber Cancer Institute, running 4 of these trials.
Enrollment posture brief
Registry condition gastrointestinal-cancer
OPEN 31 | RECR 62% | LATE 2 | EARLY 21 | RANK #277 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Advanced Breast Cancer (62% recruiting · 29 trials)
Gastrointestinal Cancer lists 31 open slots (62% of 50 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Gastrointestinal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Gastrointestinal Cancer is recruiting above its size-band peers.
31 of 50 indexed trials (62%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Gastrointestinal Cancer trials is spread across many organizations.
Dana-Farber Cancer Institute accounts for 4 of 50 trials (8%). 36 distinct sponsors appear on at least one study for this condition label.
-
Typical Gastrointestinal Cancer enrolment sits around 120 participants.
Median target enrolment is 120 among the 50 trials that report a genuine target (sentinel values excluded). 18 of those (36%) plan for fewer than 100 participants.
-
Gastrointestinal Cancer research is mostly interventional.
43 interventional and 7 observational studies make up this index (86% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
50 total, page 1 of 1
Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05995821
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Revolution Medicines
NCT06445062
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
University of Chicago
NCT04541381
BOLSTER: Learning New Skills to Thrive
Dana-Farber Cancer Institute
NCT06936878
Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer
National Cancer Institute (NCI)
NCT01313442
Improving Comprehensive Care of Cancer Patients
Baylor College of Medicine
NCT05323409
REmote Symptom COllection to improVE postopeRative Care
Medstar Health Research Institute
NCT06190730
Resilience and Equity in Aging, Cancer, and Health (REACH)
Dana-Farber Cancer Institute
NCT04674267
A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers
Memorial Sloan Kettering Cancer Center
NCT05789485
SURGE: Supporting UnderRepresented Minorities in Genomics-based Cancer Trial Enrollment (Intervention)
Nadine McCleary, MD, MPH
NCT05375643
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
National Cancer Institute (NCI)
NCT06253520
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Case Comprehensive Cancer Center
NCT06263088
Goals of Care Discussion for Patients With Advanced Lung and Gastrointestinal Cancer in the Emergency Department of a Comprehensive Cancer Center
M.D. Anderson Cancer Center
NCT06420206
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
Merck Sharp & Dohme
NCT06596694
Disease Outcomes and Toxicities in Patients With Gastrointestinal and Sarcomatous Malignancies
UNC Lineberger Comprehensive Cancer Center
NCT05743426
Dyadic Sleep Study
University of Miami
NCT06569693
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
Orlando Health
NCT06340620
Fatigue and Molecular Mechanisms in Cancer Patients Receiving CCRT
University of California, San Francisco
NCT06633224
Evaluating Microarray Pharmacogenetic Testing in Cancer Patients
Wake Forest University Health Sciences
NCT06489041
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
National Cancer Institute (NCI)
NCT03190941
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics
NCT06582017
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Washington University School of Medicine
NCT04354064
Remote Resistance Exercise Powering Survivors - Gastrointestinal Oncology
H. Lee Moffitt Cancer Center and Research Institute
NCT05664178
ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy
Abramson Cancer Center at Penn Medicine
NCT05318027
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
National Cancer Institute (NCI)
NCT04847063
sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
Rutgers, The State University of New Jersey
NCT05332002
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Memorial Sloan Kettering Cancer Center
NCT05837767
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Henry Ford Health System
NCT06065371
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
Fox Chase Cancer Center
NCT05274048
Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)
Cedars-Sinai Medical Center
NCT07124351
PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis
University of California, Irvine
NCT06511037
Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)
Dana-Farber Cancer Institute
NCT05629065
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
Merck Sharp & Dohme
NCT06864169
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Brigham and Women's Hospital
NCT04899908
Frailty in Patients With Gastrointestinal Cancer Who Are Undergoing Major Surgery
The Guthrie Clinic
NCT05694338
Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring
Carevive Systems
NCT05587972
Advancing Nursing Practices in Hospital Oncology Care
Memorial Sloan Kettering Cancer Center
NCT05053191
Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population
University of Oklahoma
NCT05863052
Avatrombopag vs. Placebo for CIT in GI Malignancies
Hanny Al-Samkari, MD
NCT05772546
Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers
University of Nebraska
NCT05220046
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
City of Hope Medical Center
NCT02293954
Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study
Stanford University
NCT03245788
Perioperative Palliative Care Surrounding Cancer Surgery for Patients & Their Family Members
Stanford University
NCT03611309
Routine Evaluation of the Social Determinants of Health in Oncology: User-centered Resource Coordination and Engagement
Dana-Farber Cancer Institute
NCT04879927
Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)
Cedars-Sinai Medical Center
NCT03723447
Rocking Motion: Physiologic Effect on the Surgical Stress Response
M.D. Anderson Cancer Center
NCT01200316
Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function
Sanofi
NCT00094965
Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer
M.D. Anderson Cancer Center
NCT02092298
CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater
M.D. Anderson Cancer Center
NCT01202409
The Science of the Art of Palliative Care
Dartmouth-Hitchcock Medical Center
NCT05137782
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 9 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Gastrointestinal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Gastrointestinal Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Gastrointestinal Cancer page
50 registered trials, 31 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 31 Gastrointestinal Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Dana-Farber Cancer Institute sponsors the most Gastrointestinal Cancer trials on record, review their full trial history before evaluating a specific study. See Dana-Farber Cancer Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gastrointestinal Cancer condition card totals 50 registered trials; most-linked intervention Mitomycin C; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.